SG11201706118XA - Nanocapsules carrying chikungunya-associated peptides - Google Patents

Nanocapsules carrying chikungunya-associated peptides

Info

Publication number
SG11201706118XA
SG11201706118XA SG11201706118XA SG11201706118XA SG11201706118XA SG 11201706118X A SG11201706118X A SG 11201706118XA SG 11201706118X A SG11201706118X A SG 11201706118XA SG 11201706118X A SG11201706118X A SG 11201706118XA SG 11201706118X A SG11201706118X A SG 11201706118XA
Authority
SG
Singapore
Prior art keywords
chikungunya
associated peptides
nanocapsules
carrying
nanocapsules carrying
Prior art date
Application number
SG11201706118XA
Inventor
Fong Poh Lisa Ng
Yiu-Wing Jason Kam
Wei Ling Wendy Lee
Fok Moon Lum
Sierin Lim
Kang Yu
Chengxun Su
Original Assignee
Agency Science Tech & Res
Univ Nanyang Tech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agency Science Tech & Res, Univ Nanyang Tech filed Critical Agency Science Tech & Res
Publication of SG11201706118XA publication Critical patent/SG11201706118XA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5176—Compounds of unknown constitution, e.g. material from plants or animals
    • A61K9/5184—Virus capsids or envelopes enclosing drugs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/18—Togaviridae; Flaviviridae
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Botany (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
SG11201706118XA 2015-01-29 2016-01-29 Nanocapsules carrying chikungunya-associated peptides SG11201706118XA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SG10201500725U 2015-01-29
PCT/SG2016/050046 WO2016122414A1 (en) 2015-01-29 2016-01-29 Nanocapsules carrying chikungunya-associated peptides

Publications (1)

Publication Number Publication Date
SG11201706118XA true SG11201706118XA (en) 2017-08-30

Family

ID=56543865

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201706118XA SG11201706118XA (en) 2015-01-29 2016-01-29 Nanocapsules carrying chikungunya-associated peptides

Country Status (5)

Country Link
US (1) US10420830B2 (en)
EP (1) EP3250233A4 (en)
CN (1) CN107405393A (en)
SG (1) SG11201706118XA (en)
WO (1) WO2016122414A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201911421VA (en) 2016-10-07 2020-02-27 Nat Univ Singapore Compositions and methods for protein expression and delivery
JP2020518648A (en) 2017-05-08 2020-06-25 グリットストーン オンコロジー インコーポレイテッド Alphavirus neonatal antigen vector
KR102076917B1 (en) * 2018-10-25 2020-02-13 연세대학교 산학협력단 Expression vector system for preparing recombinant self-assembled nanoparticles, and method of using the same
CN109730976B (en) 2018-12-24 2020-06-09 华中科技大学 Method for preparing albumin nanoparticles based on free radical oxidation
SG11202113187WA (en) 2019-05-30 2021-12-30 Gritstone Bio Inc Modified adenoviruses
EP4125944A4 (en) * 2020-04-03 2024-08-14 Gritstone Bio Inc Infectious disease antigens and vaccines
WO2022032196A2 (en) 2020-08-06 2022-02-10 Gritstone Bio, Inc. Multiepitope vaccine cassettes
EP4277654A1 (en) 2021-01-18 2023-11-22 Conserv Bioscience Limited Coronavirus immunogenic compositions, methods and uses thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1659187A (en) * 2002-05-10 2005-08-24 新世纪药品有限公司 Ferritin fusion proteins for use in vaccines and other applications
CA2593176A1 (en) * 2005-01-05 2006-07-13 Peter D. Katsikis Delivery vehicles, bioactive substances and viral vaccines
US20090035389A1 (en) 2007-02-23 2009-02-05 Specigen Inc. Targeted protein cages
MX350501B (en) * 2007-10-12 2017-09-07 Massachusetts Inst Technology Vaccine nanotechnology.
WO2009109428A2 (en) * 2008-02-01 2009-09-11 Alpha-O Peptides Ag Self-assembling peptide nanoparticles useful as vaccines
DE102008012059A1 (en) 2008-02-29 2009-09-03 Henkel Ag & Co. Kgaa Hair treatment remedy with goji extract
WO2012078116A1 (en) * 2010-12-10 2012-06-14 Agency For Science, Technology And Research Immunogenic chikungunya virus peptides
WO2012162428A1 (en) 2011-05-23 2012-11-29 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Prime-boost vaccination for viral infection
DK178233B1 (en) * 2012-09-17 2015-09-14 Novartis Tiergesundheit Ag Fiskevaccine
EP2712871A1 (en) * 2012-09-27 2014-04-02 Institut Pasteur Recombinant Measles virus expressing Chikungunya virus polypeptides and their applications
WO2014160463A1 (en) * 2013-03-13 2014-10-02 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Prefusion rsv f proteins and their use
CA2925201A1 (en) * 2013-09-24 2015-04-02 Massachusetts Institute Of Technology Self-assembled nanoparticle vaccines

Also Published As

Publication number Publication date
EP3250233A4 (en) 2018-07-25
WO2016122414A1 (en) 2016-08-04
EP3250233A1 (en) 2017-12-06
US10420830B2 (en) 2019-09-24
US20180008690A1 (en) 2018-01-11
CN107405393A (en) 2017-11-28

Similar Documents

Publication Publication Date Title
GB201520559D0 (en) Peptides
SG11201706118XA (en) Nanocapsules carrying chikungunya-associated peptides
GB201520575D0 (en) Peptides
HUE066008T2 (en) Peptides from piwil1
GB201520536D0 (en) Peptides
GB201520545D0 (en) Peptides
GB201520563D0 (en) Peptides
GB201520550D0 (en) Peptides
GB201520544D0 (en) Peptides
GB201520539D0 (en) Peptides
GB201520541D0 (en) Peptides
GB201520562D0 (en) Peptides
GB201520543D0 (en) Peptides
GB201520567D0 (en) Peptides
GB201520566D0 (en) Peptides
GB201520568D0 (en) Peptides
GB201520557D0 (en) Peptides
GB201520548D0 (en) Peptides
GB201520564D0 (en) Peptides
GB201520542D0 (en) Peptides
GB201520570D0 (en) Peptides
GB201520558D0 (en) Peptides
GB201520534D0 (en) Peptides
GB201520565D0 (en) Peptides
GB201520556D0 (en) Peptides